report from bioshares

Some paragraphs from bioshares worth posting.



Specific royalty rates were not disclosed. However, we understand that royalty rates for the vaccine are better than those achieved in the first deal with Merial, and are in double-digit territory.

Although the stock was in a pause position while a new partner was being sort and licensing negotiations were underway, we expect the stock to offer an attractive upside in the next twelve months.
Since 2003, approximately $10 million has been invested in the company, with more than $4 million received in licensing and related payments. The company possesses a platform technology with patents extending the life of potential products out to 2028.